# Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

> **NCT02334254** · PHASE4 · UNKNOWN · sponsor: **Beijing Anzhen Hospital** · enrollment: 420 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** rivaroxaban and ticagrel therapy
- **DRUG:** triple antithrombotic regimen with warfarin, asipirin and clopidogrel

## Key facts

- **NCT ID:** NCT02334254
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334254, "Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02334254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*